NCT03349073View on ClinicalTrials.gov

An Extension Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

September 14, 2017

Primary Completion Date

June 24, 2019

Study Completion Date

June 24, 2019

Conditions
Advanced Refractory Solid Tumors
Interventions
DRUG

T-1101 (Tosylate)

T-1101 (Tosylate) powder in bottle

Trial Locations (4)

105

Taipei Medical University Hospital, Taipei

704

National Cheng Kung University (NCKU) Hospital, Tainan City

Unknown

China Medical University Hospital, Taichung

National Taiwan University Hospital, Taipei

All Listed Sponsors
lead

Taivex Therapeutics Corporation

INDUSTRY

NCT03349073 - An Extension Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors | Biotech Hunter | Biotech Hunter